Complement C3a/C3a Des-Arg (Neo-epitope des-Arg) antibody
Reactivity: Human
IA, FACS, IHC (p), WB
Host: Mouse
Monoclonal
2991
unconjugated
-
- Target
- Complement C3a/C3a Des-Arg
- Binding Specificity
- Neo-epitope des-Arg
- Reactivity
- Human
- Host
- Mouse
- Clonality
- Monoclonal
- Application
- Immunoassay (IA), Flow Cytometry (FACS), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Western Blotting (WB)
- Sterility
- 0.2 μm filtered
- Clone
- 2991
-
- Application Notes
- For Western blotting, dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50. Positive Activated human serum or purified human C3adesArg protein control Negative For Western blot, any irrelevant protein can be used. control
- Restrictions
- For Research Use only
-
- Buffer
- PBS, containing 0.1 % bovine serum albumin and 0.02 % sodium azide.
- Preservative
- Sodium azide
- Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Storage
- 4 °C
- Storage Comment
- Product should be stored at 4 °C. Under recommended storage conditions, product is stable for at least one year. The exact expiry date is indicated on the label.
-
- Target
- Complement C3a/C3a Des-Arg
- Background
- The monoclonal antibody 2991 recognizes the neo-epitope of human C3a/C3a-desArg that is formed upon cleavage of the complement protein C3 into C3a and C3b. The complement system is an important part of the humoral response in innate immunity, consisting of three different pathways. The third complement component, C3, is central to the classical, alternative and lectin pathways of complement activation. Activation products of the complement cascade contain neo-epitopes that are not present in the individual native components. Monoclonal antibodies detecting neo-epitopes have been used for direct quantification of activation at different steps in the complement cascade. The synthesis of C3 is tissue-specific and is modulated in response to a variety of stimulatory agents. C3 is the most abundant protein of the complement system with serum protein levels of about 1.3 mg/mL. An inherited deficiency of C3 predisposes the person to frequent assaults of bacterial infections. In ulcerative colitis, and idiopathic chronic inflammatory bowel disease, the deposition of C3 in the diseased mucosa has been reported. Proteolysis by certain enzymes results in the cleavage of C3 releasing C3a anaphylatoxin and C3b. C3a is a protein of 74 amino acids. C3a itself is very short-lived and in serum is cleaved rapidly into the more stable C3a-desArg (also called acylation stimulating protein, ASP) . Therefore, measurement of C3a-desArg allows reliable conclusions about the level of complement activation in the test samples. C3a is a mediator of local inflammatory processes. It induces smooth muscle contraction, increases vascular permeability, and causes histamine release from mast cells and basophilic leukocytes. C3a is involved in inflammatory reactions seen in gram- negative bacterial sepsis, trauma, ischemic heart disease, post-dialysis syndrome and a variety of autoimmune diseases. Normal values in plasma of control persons range between 48 - 150 ng/mL (median: 86.4 ng/mL, SD: 29.3 ng/mL) Monoclonal antibody 2991 recognizes both C3a and C3a-desArg, with at least a 5x higher preference for C3a-desArg. Aliases Acylation stimulating protein, ASP Immunogen Human C3a des-Arg
-
You are here:
